Pheochromocytoma/paraganglioma-associated cardiomyopathy

Pheochromocytoma/paraganglioma (PPGL) are neuroendocrine tumors that frequently produce and release catecholamines. Catecholamine excess can manifest in several cardiovascular syndromes, including cardiomyopathy. PPGL-induced cardiomyopathies occur in up to 11% of cases and are most often associated...

Full description

Bibliographic Details
Main Authors: Alicja Szatko, Piotr Glinicki, Małgorzata Gietka-Czernel
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-07-01
Series:Frontiers in Endocrinology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2023.1204851/full
_version_ 1797780845888536576
author Alicja Szatko
Alicja Szatko
Piotr Glinicki
Piotr Glinicki
Małgorzata Gietka-Czernel
author_facet Alicja Szatko
Alicja Szatko
Piotr Glinicki
Piotr Glinicki
Małgorzata Gietka-Czernel
author_sort Alicja Szatko
collection DOAJ
description Pheochromocytoma/paraganglioma (PPGL) are neuroendocrine tumors that frequently produce and release catecholamines. Catecholamine excess can manifest in several cardiovascular syndromes, including cardiomyopathy. PPGL-induced cardiomyopathies occur in up to 11% of cases and are most often associated with an adrenal pheochromocytoma (90%) and rarely with a paraganglioma derived from the sympathetic ganglia (10%). PPGL-associated cardiomyopathies can be chronic or acute, with takotsubo cardiomyopathy being the most often reported. These two types of PPGL-induced cardiomyopathy seem to have different pathophysiological backgrounds. Acute catecholaminergic stress inundates myocardial β-adrenoceptors and leads to left ventricle stunning and slight histological apoptosis. In chronic cardiomyopathy, prolonged catecholamine exposure leads to extended myocardial fibrosis, inflammation, and necrosis, and ultimately it causes dilated cardiomyopathy with a low ejection fraction. Sometimes, especially in cases associated with hypertension, hypertrophic cardiomyopathy can develop. The prognosis appears to be worse in chronic cases with a higher hospital mortality rate, higher cardiogenic shock rate at initial presentation, and lower left ventricular recovery rate after surgery. Therefore, establishing the correct diagnosis at an early stage of a PPGL is essential. This mini-review summarizes current data on pathophysiological pathways of cardiac damage caused by catecholamines, the clinical presentation of PPGL-induced cardiomyopathies, and discusses treatment options.
first_indexed 2024-03-12T23:49:34Z
format Article
id doaj.art-a6d5d4a9e7c5481aa07edaf49255038c
institution Directory Open Access Journal
issn 1664-2392
language English
last_indexed 2024-03-12T23:49:34Z
publishDate 2023-07-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Endocrinology
spelling doaj.art-a6d5d4a9e7c5481aa07edaf49255038c2023-07-13T19:45:09ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922023-07-011410.3389/fendo.2023.12048511204851Pheochromocytoma/paraganglioma-associated cardiomyopathyAlicja Szatko0Alicja Szatko1Piotr Glinicki2Piotr Glinicki3Małgorzata Gietka-Czernel4Department of Endocrinology, Centre of Postgraduate Medical Education, Warsaw, PolandEndoLab Laboratory, Centre of Postgraduate Medical Education, Warsaw, PolandDepartment of Endocrinology, Centre of Postgraduate Medical Education, Warsaw, PolandEndoLab Laboratory, Centre of Postgraduate Medical Education, Warsaw, PolandDepartment of Endocrinology, Centre of Postgraduate Medical Education, Warsaw, PolandPheochromocytoma/paraganglioma (PPGL) are neuroendocrine tumors that frequently produce and release catecholamines. Catecholamine excess can manifest in several cardiovascular syndromes, including cardiomyopathy. PPGL-induced cardiomyopathies occur in up to 11% of cases and are most often associated with an adrenal pheochromocytoma (90%) and rarely with a paraganglioma derived from the sympathetic ganglia (10%). PPGL-associated cardiomyopathies can be chronic or acute, with takotsubo cardiomyopathy being the most often reported. These two types of PPGL-induced cardiomyopathy seem to have different pathophysiological backgrounds. Acute catecholaminergic stress inundates myocardial β-adrenoceptors and leads to left ventricle stunning and slight histological apoptosis. In chronic cardiomyopathy, prolonged catecholamine exposure leads to extended myocardial fibrosis, inflammation, and necrosis, and ultimately it causes dilated cardiomyopathy with a low ejection fraction. Sometimes, especially in cases associated with hypertension, hypertrophic cardiomyopathy can develop. The prognosis appears to be worse in chronic cases with a higher hospital mortality rate, higher cardiogenic shock rate at initial presentation, and lower left ventricular recovery rate after surgery. Therefore, establishing the correct diagnosis at an early stage of a PPGL is essential. This mini-review summarizes current data on pathophysiological pathways of cardiac damage caused by catecholamines, the clinical presentation of PPGL-induced cardiomyopathies, and discusses treatment options.https://www.frontiersin.org/articles/10.3389/fendo.2023.1204851/fullpheochromocytomaparagangliomadilated cardiomyopathyhypertrophic cardiomyopathytakotsubo cardiomyopathy
spellingShingle Alicja Szatko
Alicja Szatko
Piotr Glinicki
Piotr Glinicki
Małgorzata Gietka-Czernel
Pheochromocytoma/paraganglioma-associated cardiomyopathy
Frontiers in Endocrinology
pheochromocytoma
paraganglioma
dilated cardiomyopathy
hypertrophic cardiomyopathy
takotsubo cardiomyopathy
title Pheochromocytoma/paraganglioma-associated cardiomyopathy
title_full Pheochromocytoma/paraganglioma-associated cardiomyopathy
title_fullStr Pheochromocytoma/paraganglioma-associated cardiomyopathy
title_full_unstemmed Pheochromocytoma/paraganglioma-associated cardiomyopathy
title_short Pheochromocytoma/paraganglioma-associated cardiomyopathy
title_sort pheochromocytoma paraganglioma associated cardiomyopathy
topic pheochromocytoma
paraganglioma
dilated cardiomyopathy
hypertrophic cardiomyopathy
takotsubo cardiomyopathy
url https://www.frontiersin.org/articles/10.3389/fendo.2023.1204851/full
work_keys_str_mv AT alicjaszatko pheochromocytomaparagangliomaassociatedcardiomyopathy
AT alicjaszatko pheochromocytomaparagangliomaassociatedcardiomyopathy
AT piotrglinicki pheochromocytomaparagangliomaassociatedcardiomyopathy
AT piotrglinicki pheochromocytomaparagangliomaassociatedcardiomyopathy
AT małgorzatagietkaczernel pheochromocytomaparagangliomaassociatedcardiomyopathy